CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

The UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI-PGx) have developed guidance on CYP2C19 genotype testing for clopidogrel. This guidance is compatible with NICE healthtech guidance 724 but also makes recommendations in other areas.

Disclaimer

This is a resource you may find helpful to support implementation. It has not been produced by NICE and is not maintained by NICE. In the event of any issues or errors, please contact CERSI-PGx.